SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm gets US FTC’s nod for acquiring 100% of membership interest in Lannett

19 Jun 2026 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc. has received the necessary approval from US Federal Trade Commission (FTC) for the acquisition of the 100% of membership interest in Lannett Company LLC (Lannett) from Lannett Seller Holdco, Inc.

Earlier, Aurobindo Pharma USA Inc had entered into a definitive agreement with Lannett Seller Holdco Inc for the same. The transaction aligns with the company’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities.

Through this acquisition, the company will gain access to: a complementary portfolio of profitable products, a growing Contract Development and Manufacturing Organization (CDMO) business, and a U.S.-based manufacturing facility with significant excess capacity (425k sq. ft facility with around 3.6bn doses capacity) and with potential for further expansion. The cost of said acquisition is based on an enterprise value of $250 million (Rs 2185 crore) on a cash free debt free basis and including normalized levels of working capital.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1554.95 25.25 (1.65%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: